A cohort study of antihyperglycemic medication exposure and survival in patients with gastric cancer

Dulskas, Audrius; Patašius, Aušvydas; Linkeviciute-Ulinskiene, Donata; Zabulienė, Lina; Smailytė, Giedrė

doi:10.18632/aging.102245

Cited by 22 publications

(13 citation statements)

References 32 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were agreement with results obtained by Alehagen et al (12) who found that, there were significant differences between T2DM and IFG according to CoQ10 (P < 0.001). Dulskas et al, (13) found that, there were no significant difference between T2DM and IFG according to age (P 0.89), BMI (P 0.74), this result was agreement with results in this study. A study of (14) found that, there were significant differences IGFBP in patients with T2DM.…”

Section: Discussionsupporting

confidence: 92%

Role of CoQ10 and IGFBP-1 in Obese Male Patients with Diabetic Mellitus Type II

Al-Khafajy¹,

Khaleel²

2021

IJFMT

View full text Add to dashboard Cite

Study the role of CoQ10 and IGFBP-1 in obese male patients with diabetic mellitus type 2. ELISA method was used to assay Serum CoQ10 and IGFBP-1. Blood was taken with drawn sample from 30 obese normal patients with age range (40-60) years, 30 diabetic patients with age range (40-60) years at duration of disease (1-5) years and 30 normal healthy patients. The mean difference between T2DM according to CoQ10 (12.5±1.1) was decreased than the mean of IFG (21.8±3.2) (P 0.002) and the mean difference between T2DM according to IGFBPs (0.65±0.06) was decreased than the mean of IFG (3.2±0.3) (P 0.000). While no significant difference between mean age of DM2 patients (55.5±1.06), and IFG (55.6±0.9) (p 0.90), no significant difference between mean BMI of DM2 patients (27.7±0.8), and IFG (27.8±0.5) (p 0.94). there were significant differences in DM and IFG obese groups (G1 and G2) according to age (51.66 ±2.10, 51.80±1.16) P (0.02), however, there were significant differences between DM and IFG in Normal weight groups (G5 and G6) according to age (59.93±0.94, 51.13±1.80) P (0.00), while no significant differences between DM and IFG in Over weight groups (G3 and G4) according to age (54.93±1.17, 58.00±1.73) p(0.21), there were significant differences between DM2 and IFG in obese groups (G1 and G2) according to BMI (33.70±1.20, 31.11±0.37) P (0.01), ), no significant difference between overweight (G3 and G4) according to BMI (27.72±0.30, 27.52±0.34) P(0.66), and no significant difference between normal weight (G5 and G6) according to BMI (21.84±0.45, 21.53±0.50) P(0.65). There were significant differences between DM and IFG in obese groups (G1 and G2) according to CoQ10 (7.2±0.4, 4.9±0.4) P (0.002), and IGFBP (0.3±0.02, 1.2±0.19) P (0.005).

show abstract

Section: Discussionsupporting

confidence: 92%

Role of CoQ10 and IGFBP-1 in Obese Male Patients with Diabetic Mellitus Type II

Al-Khafajy¹,

Khaleel²

2021

IJFMT

View full text Add to dashboard Cite

show abstract

“…Regarding the GII combination treatment, although the GH-cancer relationship has been a subject of discussion (38), previous in vitro and in vivo studies have demonstrated that it does not exhibit pro-tumor effects (39)(40)(41). Furthermore, although insulin promotes malignant cell proliferation and invasiveness in vitro (42,43), however, contradictory effects have been reported regarding cancer survival and risk in patients (44)(45)(46). According to these studies, in the present model, GII treatment did not show pro-tumor effects, although GII-treated cells expressed GH and insulin receptors, as well as cyclooxygenase (data not shown).…”

Section: Discussionmentioning

confidence: 50%

The combination of orlistat, lonidamine and 6‑diazo‑5‑oxo‑L‑norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells

et al. 2020

View full text Add to dashboard Cite

Cancer upregulates glycolysis, glutaminolysis and lipogenesis, and induces a catabolic state in patients. The concurrent inhibition of both tumor anabolism and host catabolism, and the energetic consequences of such an approach, have not previously been fully investigated. In the present study, CT26.WT murine colon cancer cells were treated with the combination of anti-anabolic drugs orlistat, lonidamine and 6-diazo-5-oxo-L-norleucine (DON; OLD scheme), which are inhibitors of the de novo synthesis of fatty acids, glycolysis and glutaminolysis, respectively. In addition, the effects of OLD scheme sumplemented with the combination of anti-catabolic compounds, namely growth hormone, insulin and indomethacin (GII scheme), were also evaluated. The effects of the compounds used in combination on CT26.WT cell viability, clonogenicity and energetic metabolism were assessed in vitro. The results demonstrated that the anti-anabolic approach reduced cell viability, clonogenicity and cell cycle progression, and increased apoptosis. These effects were associated with decreased oxidative phosphorylation, glycolysis and fuel flexibility. Furthermore, the anti-catabolic scheme, alone or supplemented with anti-anabolic compounds, did not favor tumor growth. These findings indicated that the simultaneous pharmacological inhibition of tumor anabolism and host catabolism exhibits antitumor effects that should be further evaluated.

show abstract

“…Regarding the GII combination, despite that GH raises concerns about its pro-tumoral effects 30 , in vitro and in vivo studies demonstrate that it does not stimulate cancer progression [31][32][33] . Insulin, on the other hand, does increase malignant cell proliferation and invasiveness 34,35 , but these effects are at least inconsistent regarding cancer risk and survival in patients [36][37][38] . According with these studies, in our model neither GH, insulin, nor indomethacin modified cancer growth in vitro or in vivo.…”

Section: Discussionmentioning

confidence: 99%

Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy

Schcolnik‐Cabrera

Chávez‐Blanco

Domínguez-Gómez

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The malignant energetic demands are satisfied through glycolysis, glutaminolysis and de novo synthesis of fatty acids, while the host curses with a state of catabolism and systemic inflammation. The concurrent inhibition of both, tumor anabolism and host catabolism, and their effect upon tumor growth and whole animal metabolism, have not been evaluated. We aimed to evaluate in colon cancer cells a combination of six agents directed to block the tumor anabolism (orlistat + lonidamine + DON) and the host catabolism (growth hormone + insulin + indomethacin). Treatment reduced cellular viability, clonogenic capacity and cell cycle progression. These effects were associated with decreased glycolysis and oxidative phosphorylation, leading to a quiescent energetic phenotype, and with an aberrant transcriptomic landscape showing dysregulation in multiple metabolic pathways. The in vivo evaluation revealed a significant tumor volume inhibition, without damage to normal tissues. The six-drug combination preserved lean tissue and decreased fat loss, while the energy expenditure got decreased. Finally, a reduction in gene expression associated with thermogenesis was observed. Our findings demonstrate that the simultaneous use of this six-drug combination has anticancer effects by inducing a quiescent energetic phenotype of cultured cancer cells. Besides, the treatment is well-tolerated in mice and reduces whole animal energetic expenditure and fat loss.

show abstract

A cohort study of antihyperglycemic medication exposure and survival in patients with gastric cancer

Cited by 22 publications

References 32 publications

Role of CoQ10 and IGFBP-1 in Obese Male Patients with Diabetic Mellitus Type II

Role of CoQ10 and IGFBP-1 in Obese Male Patients with Diabetic Mellitus Type II

The combination of orlistat, lonidamine and 6‑diazo‑5‑oxo‑L‑norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells

Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy

Contact Info

Product

Resources

About